Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hete rocyclic derivatives

A technology of derivatives and heterocycles, applied in drug combinations, metabolic diseases, cardiovascular system diseases, etc., can solve problems such as no established correlation

Inactive Publication Date: 2003-07-16
NIPPON SHINYAKU CO LTD
View PDF19 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Although it has been discussed many times before that the blood triglyceride level may be an important risk factor for atherosclerosis, a clear correlation has not been established

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

reference example 1

[0223] (4-Chlorobutyl)diethylmalonate

[0224] In 458 ml of dry tetrahydrofuran (THF), 13.4 g of 60% sodium hydride was added, and 160.6 g of diethyl malonate was added dropwise with ice-cooling and stirring. After dropping, stir for 15 minutes, then add 57.3 g of 1-bromo-4-chlorobutane, and stir at room temperature for 50 hours. The reaction solution was poured into ice water, neutralized with dilute hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated. The residue was distilled under reduced pressure to obtain 26.8 g of the title compound as a colorless oil.

[0225] Boiling point 127~130℃(5mmHg)

[0226] The following compounds were produced in the same manner as in Reference Example 1.

[0227] (3-Chloropropyl)diethylmalonate

[0228] Diethyl (5-chloropentyl)malonate

reference example 2

[0230] Diethyl (5-hexenyl)malonate

[0231] In 120 ml of dry tetrahydrofuran (THF), 4.9 g of 60% sodium hydride was added, and 29.5 g of diethyl malonate was added dropwise with ice-cooling and stirring. After the dropwise addition, stir for 15 minutes, then add 10 g of 6-bromo-1-hexane, and heat to reflux for 21 hours. The reaction solution was cooled, poured into ice water, neutralized with dilute hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (Wakogel (registered trademark) C-200, n-hexane:ethyl acetate=20:1) to obtain 14.5 g of the title compound as a yellow oil.

[0232] 1 H-NMR (CDCl 3 )δ: 1.23~1.47(10H, m), 1.84~2.11(4H, m),

[0233] 3.28~3.37(1H, m), 4.14~4.25(4H, m), 4.91~5.05(2H, m),

[0234] 5.69~5.90(1H,m)

reference example 3

[0236] 6-Chloro-2-hydroxymethyl-1-hexanol

[0237] In 214 ml of dry diethyl ether, 8 g of lithium aluminum hydride was added, and a solution of 26.7 g of 4-chlorobutyldiethylmalonate / 53 ml of diethyl ether was added dropwise with ice-cooling and stirring. Stir at room temperature for 1 hour, then cool in ice water, and add 173 ml tetrahydrofuran / 14.7 ml water dropwise. Next, 14.7 ml of 1N sodium hydroxide and 35 ml of water were added, stirred for 15 minutes, then filtered to remove insoluble matter, and the filtrate was concentrated to obtain 18.2 g of the title compound as a colorless oil.

[0238] 1 H-NMR (CDCl 3 )δ: 1.22~1.38(2H, m), 1.42~1.58(2H, m),

[0239] 1.68~1.88(3H,m), 2.36~2.44(2H,m), 3.55(2H,t),

[0240] 3.61~3.72(2H, m), 3.77~3.88(2H, m)

[0241] The following compounds were produced in the same manner as in Reference Examples.

[0242] 5-Chloro-2-hydroxymethyl-1-hexanol,

[0243] 7-Chloro-2-hydroxymethyl-1-heptanol,

[0244] 2-Hydroxymethyl-7-octen-1-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
boiling pointaaaaaaaaaa
boiling pointaaaaaaaaaa
boiling pointaaaaaaaaaa
Login to View More

Abstract

The present invention provides a prophylactic and therapeutic agent for hyperlipidemia comprising a heterocyclic derivative represented by the following formula [1] or a medically acceptable salt thereof as an active ingredient, and a heterocyclic derivative represented by the formula [1] including The new compound: R 1 -Het-D-E [1] [wherein, R 1 represents an optionally substituted aryl group or an optionally substituted aromatic heterocyclic group. Het represents a divalent aromatic heterocyclic group. D represents an alkylene group, an alkenylene group, an alkynylene group, or the like. E represents carboxylic acid, etc.] The compound of the present invention has the effect of lowering blood triglycerides, lowering LDL-C, and lowering blood sugar. Therefore, it is effective in hyperlipidemia, arteriosclerosis, diabetes, hypertension and It is useful for the prevention or treatment of obesity and the like.

Description

technical field [0001] The present invention relates to novel heterocyclic derivatives (heterocyclic compounds) or pharmaceutically acceptable salts thereof. [0002] The compound of the present invention has the effect of lowering blood triglycerides and lowering low-density lipoprotein cholesterol (hereinafter referred to as LDL-C), and also has the effect of lowering blood sugar and blood insulin, or has the effect of increasing hyperlipidemia The effect of high-density lipoprotein cholesterol (hereinafter referred to as HDL-C) or the reduction of arteriosclerosis index [the ratio of non-high-density lipoprotein cholesterol to HDL-C, calculated by (total cholesterol value-HDL-C value) / HDL-C value ], it is useful in the prevention or treatment of coronary artery disease, cerebral infarction, hyperlipidemia, arteriosclerosis or diabetes. Background technique [0003] Insulin resistance syndrome complicated with abnormal glucose and lipid metabolism and hypertension is attr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4178A61K31/421A61K31/422A61K31/426A61K31/427A61K31/4439A61P3/04A61P3/06A61P3/10A61P9/10A61P9/12C07D263/32C07D277/24C07D277/30C07D405/06C07D413/04C07D413/06C07D413/12C07D413/14C07D417/06
CPCC07D405/06C07D263/32C07D277/24C07D413/04A61K31/421C07D413/14A61K31/422A61K31/427C07D413/12A61K31/4439A61K31/426C07D413/06A61K31/4178A61P3/10A61P3/04A61P3/06A61P9/10A61P9/12
Inventor 桑原健誌青木富义
Owner NIPPON SHINYAKU CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com